Chardan analyst Geulah Livshits raised the firm’s price target on Intellia Therapeutics to $129 from $121 and keeps a Buy rating on the shares after the company discussed updated phase I dose escalation data on in vivo gene editing asset NTLA-2002 in hereditary angioedema, or HAE. Livshits continues to "be impressed with the translatability of Intellia’s in vivo editing program" and believes the results "bode well" for NTLA-2003, the analyst tells investors.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NTLA:
- Intellia presents new interim data from first-in-human study of NTLA-2002 in HAE
- Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific Meeting
- Sell these stocks now, proven algorithm says
